199.92 USD
+0.18 (+0.09%)
199.95 USD
+0.03 (+0.02%)
Overall RXDX gets a fundamental rating of 4 out of 10. We evaluated RXDX against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RXDX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, RXDX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- RXDX had negative earnings in the past year.
- In the past year RXDX has reported a negative cash flow from operations.
1.2 Ratios
- RXDX has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RXDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, RXDX has more shares outstanding
- There is no outstanding debt for RXDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- RXDX has an Altman-Z score of 94.07. This indicates that RXDX is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 94.07, RXDX belongs to the best of the industry, outperforming 99.20% of the companies in the same industry.
- There is no outstanding debt for RXDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 94.07 |
ROIC/WACCN/A
WACC8.62%
2.3 Liquidity
- A Current Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
- RXDX has a better Current ratio (37.56) than 98.56% of its industry peers.
- A Quick Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
- RXDX has a Quick ratio of 37.56. This is amongst the best in the industry. RXDX outperforms 98.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 37.56 | ||
| Quick Ratio | 37.56 |
3. Growth
3.1 Past
- RXDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.62%.
- Looking at the last year, RXDX shows a very negative growth in Revenue. The Revenue has decreased by -36.47% in the last year.
- Measured over the past years, RXDX shows a very strong growth in Revenue. The Revenue has been growing by 82.51% on average per year.
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%
3.2 Future
- RXDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.32% yearly.
- The Revenue is expected to grow by 145.93% on average over the next years. This is a very strong growth
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RXDX. In the last year negative earnings were reported.
- Also next year RXDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as RXDX's earnings are expected to decrease with -15.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
5. Dividend
5.1 Amount
- RXDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROMETHEUS BIOSCIENCES INC / RXDX FAQ
Can you provide the ChartMill fundamental rating for PROMETHEUS BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 4 / 10 to RXDX.
What is the valuation status for RXDX stock?
ChartMill assigns a valuation rating of 0 / 10 to PROMETHEUS BIOSCIENCES INC (RXDX). This can be considered as Overvalued.
Can you provide the profitability details for PROMETHEUS BIOSCIENCES INC?
PROMETHEUS BIOSCIENCES INC (RXDX) has a profitability rating of 1 / 10.
What is the financial health of PROMETHEUS BIOSCIENCES INC (RXDX) stock?
The financial health rating of PROMETHEUS BIOSCIENCES INC (RXDX) is 8 / 10.
What is the expected EPS growth for PROMETHEUS BIOSCIENCES INC (RXDX) stock?
The Earnings per Share (EPS) of PROMETHEUS BIOSCIENCES INC (RXDX) is expected to decline by -16.9% in the next year.